Tim Lu’s gene-circuit star Senti signs up for a $645M discovery alliance with Roche sub Spark
Three months after bringing in Bayer and a group of new investors in his first mega-round, Senti Bio chief Tim Lu now has the first high-profile Big Pharma alliance to help burnish his prospects for a cutting-edge breakthrough in gene therapies.
Spark Therapeutics — which Roche acquired as its base camp in gene therapy development — has turned to Senti in a collaboration aimed at using its synthetic gene circuit tech in new programs aimed at the CNS, eye and liver.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.